Clinical Value of HPV-DNA Typing Combined with TCT for Cervical Cancer Screening
Objective:To explore the clinical value of human papillomavirus(HPV)-DNA typing combined with cervical thin layer liquid based cytology(TCT)for cervical cancer screening.Methods:256 patients with cervical lesions admitted to our hospital from June 2021 to December 2022 were selected,and all participants underwent HPV-DNA typing and TCT.Using colposcopy biopsy as the gold standard,analyze the value of HPV-DNA typing test,TCT examination for single and combined diagnosis of cervical cancer,and calculate consistency.Results:Among the 256 patients with cervical lesions,156 were found to be positive through colposcopy examination,with a detection rate of 60.94％.The sensitivity,specificity,accuracy,positive predictive value,and negative predictive value of TCT and HPV-DNA combined diagnosis were 96.15％,95.00％,95.70％,96.77％,and 94.06％,respectively,higher than those of TCT and HPV-DNA,with statistically significant differences(P＜0.05).The consistency between the combined diagnosis of cervical cancer with TCT and HPV-DNA and the results of colposcopy is better than that of TCT and HPV-DNA.Conclusion:The use of HPV-DNA typing combined with TCT in cervical cancer screening can improve diagnostic accuracy and provide more reference information for clinical diagnosis and treatment.
万方数据
维普
